Skip to content

Alligator Bioscience AB Sustainability Reports

Alligator Bioscience AB is a clinical-stage biotechnology company that develops tumor-directed immunotherapies for cancer treatment. The company primarily focuses on designing bispecific antibodies and targeting the CD40 pathway to stimulate the immune system against metastatic pancreatic cancer and other oncology indications.

Sector: Professional & technical services

Country: Sweden

Exchange: Nasdaq Stockholm

ISIN: SE0024173637

11 reports from 2016 to 2025